LOXL1 and prostate cancer: Drug resistant activity of prostate cancer may be modulated by upregulation of LOXL1-AS1 and EGFR and downregulation of miR-let-7a-5p, predicting miR-let-7a-5p and EGFR are negatively regulated by LOXL1-AS1 and miR-let-7a-5p, respectively (91).